CatalystCorporate

Medpace forecasts 2026 EPS of $17.97-$18.32 as $1B buyback authorization replaces prior program

Medpace issued 2026 EPS guidance and replaced its buyback with a $1B authorization.

What changed

Medpace issued 2026 EPS guidance and replaced its buyback with a $1B authorization.

Why it matters

Medpace issued 2026 EPS guidance and replaced its buyback with a $1B authorization. — impact context not separately stored; see What changed.

Sources